# Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

> **NCT02070991** · PHASE2 · COMPLETED · sponsor: **Actelion** · enrollment: 63 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Macitentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02070991
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2015-11-01
- **Final completion:** 2015-11-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070991, "Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02070991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*